Paroxetine updated on 07-01-2025

Eye defects

id	Study   Auto Wemakor, 2015Ban (Controls unexposed, disease free), 2014Colvin, 2011Davis, 2007	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimesterPaternal exp. genotoxic window only (0–3 months preconception)Paternal exposure: epigenetic window only (3–xxx months preconception)Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception)Paternal exposure: other window	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S7350 R21486	Wemakor, 2015	Eye malformations	1st trimester	case control	unexposed (general population or NOS)	Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...)	1.37 [0.41;4.59]	3/30   825/17,881	828	30		ref
S5886 R14754	Ban (Controls unexposed, disease free), 2014	Eye malformations	1st trimester	retrospective cohort (claims database)	unexposed, disease free	Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...)	0.83 [0.12;5.76]	-/1,200   313/325,294	-	1,200		ref
S7180 R20240	Colvin, 2011	Congenital abnormalities of eye	1st trimester	retrospective cohort (claims database)	unexposed (general population or NOS)	Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...)	1.11 [0.07;17.93] C	0/572   74/94,561	74	572		ref
S7228 R20755	Davis, 2007	Congenital anomalies of eye	1st trimester	retrospective cohort (claims database)	unexposed (general population or NOS)	Adjustment: No Monotherapy: no or not specified	2.36 [1.20;4.66]	8/182   641/49,654	649	182		ref
					Total	4 studies	1.87 [1.08;3.26]		1,551	1,984
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded